9
Participants
Start Date
March 18, 2019
Primary Completion Date
December 30, 2019
Study Completion Date
December 30, 2019
Venetoclax
tablet, oral
AMG 176
solution, intravenous
Calvary Mater Newcastle /ID# 211455, Waratah
Alfred Health /ID# 210350, Melbourne
Royal Adelaide Hospital /ID# 210602, Adelaide
Charite Universitaetsklinikum Berlin - Campus Virchow /ID# 207987, Berlin
UPMC Hillman Cancer Ctr /ID# 208482, Pittsburgh
Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 207788, Hamburg
Unc /Id# 207388, Chapel Hill
University of Iowa Hospitals and Clinics /ID# 207459, Iowa City
Universitaetsklinikum Frankfurt /ID# 207984, Frankfurt am Main
Washington University-School of Medicine /ID# 206995, St Louis
Univ Kansas Med Ctr /ID# 207480, Kansas City
USC Norris Cancer Center /ID# 207396, Los Angeles
City of Hope /ID# 207393, Duarte
Duplicate_Dana-Farber Cancer Institute /ID# 207367, Boston
NYU Langone Medical Center /ID# 207390, New York
Universitaetsklinikum Leipzig /ID# 209824, Leipzig
Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 207803, Dresden
Lead Sponsor
Collaborators (2)
Genentech, Inc.
INDUSTRY
Amgen
INDUSTRY
AbbVie
INDUSTRY